Skip to main content

fluticasone propionate; salmeterol

Generic: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE·Brand: ADVAIR DISKUS 100/50, ADVAIR DISKUS 250/50, ADVAIR DISKUS 500/50, ADVAIR HFA, AIRDUO DIGIHALER, AIRDUO RESPICLICK, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, WIXELA INHUB

fluticasone propionate; salmeterol: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

fluticasone propionate; salmeterol evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect fluticasone propionate; salmeterol to TEVA; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could fluticasone propionate; salmeterol → TEVA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Development Pipeline (1)
CompanyPhase
Teva Pharmaceutical Industries Limited (TEVA)Approved
Clinical Trials (1)

Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover Phase 1/2a Study Testing Safety/Efficacy of Advair HFA (Salmeterol, Fluticasone) in Resting & Exercising Healthy & High Altitude Pulmonary Edema (HAPE) Predisposed Subjects

NCT06040268·Phase 1·UTHR
Recruiting

Primary endpoint: VO2 max

InterventionalRandomizedquadruple60 targetStarted 2023-12Completion 2026-121 site · United StatesUniversity of Colorado, Denver
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). (TEVA)FDA ↗
NDA208799Type 4 - New CombinationStandardInhalationPowder

Frequently asked questions

Who is developing fluticasone propionate; salmeterol?

fluticasone propionate; salmeterol is being developed by Teva Pharmaceutical Industries Limited.

How many clinical trials involve fluticasone propionate; salmeterol?

BioSniper tracks 1 clinical trial involving fluticasone propionate; salmeterol.

What is fluticasone propionate; salmeterol's latest FDA decision?

The most recent tracked FDA decision for fluticasone propionate; salmeterol is Approval for 1 INDICATIONS AND USAGE Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). , dated January 27, 2017.